Zacks
0
All posts from Zacks
Zacks in Our Research. Your Success.,

Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

For Immediate Release

Chicago, IL – July 10, 2017 – Today, Zacks Equity Research discusses the Industry: MedTech, Part 2, including Teleflex Inc. (NYSE: TFX Free Report ), Medtronic (NYSE: MDT Free Report ), Johnson & Johnson (NYSE: JNJ Free Report ), Hologic, Inc. (NASDAQ: HOLX Free Report ) and Wright Medical (NASDAQ: WMGI Free Report ).

Industry: MedTech, Part 2

Link: https://www.zacks.com/commentary/120647/medtech-thriving-on-...

It’s been more than six months since President Trump’s election and the medical device industry, which was earlier hopeful about the change of power in White House, is currently fussing over the inability of Republicans to come up with any healthcare policy. As of now, any reform in this respect seems a far cry. Per the latest New Republic article, “The Republican push to repeal and replace Obamacare is currently stalled in the Senate, where Majority Leader Mitch McConnell has delayed a vote until after the July 4 recess because his bill doesn’t have the necessary GOP support.”

Given the current lack of clarity, let’s concentrate on some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation. These have been driving the sector’s impressive performance despite severe socio-economic and political instability.

Also worth mentioning are the recent changes in consumer demand and market dynamics, which have led to a dramatic transformation in the healthcare system. This is evident from the growing number of minimally invasive surgeries, rising demand for liquid biopsy tests, use of IT for ensuring quick and improved patient care, and the shift of the payment system to a value-based model among others.

Let’s elaborate some of the major long-term drivers of the MedTech sector.

Major M&As

The year has started off with two MedTech mammoths joining forces. We are talking about Abbott’s colossal $25 billion consolidation with St. Jude Medical in January. The consolidated is currently on track to form a leader in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure as well as earn a leading position in the high-growth neuromodulation market.

The same month, another big merger took place, that of the acquisition of Israel-based Valtech Cardio by Edwards Lifesciences for a total deal value of $690 million. The acquisition allows Edwards Lifesciences to expand its services in the huge heart valve repair and replacement market in the emerging geographical regions.

A $1 billion merger deal was executed in February, through which Teleflex Inc. (NYSE:TFX Free Report ) acquired Vascular Solutions that develops clinical solutions for minimally invasive coronary and peripheral vascular procedures. The combination is expected to meaningfully accelerate the growth of Teleflex’s vascular and interventional businesses.

It seems that the $43-billion Medtronic (NYSE: MDT Free Report ) Covidien merger and the subsequent reports of how the consolidated company knocked off Johnson & Johnson (NYSE: JNJ Free Report ) from its indisputable position as the top firm in the medical devices space, inspired other industry leaders to come forward with mega M&A deals.

Divestments

Medical device majors continue to offload their non-core business lines, specifically to focus on the main segments and to divest assets that are similar to the ones acquired through mergers. These divestures have been mandated by the U.S. Federal Trade Commission (FTC) and other international anti-trust regulators. This restricts chances of monopoly in the market.

Let’s take a look at some of the significant divestments in recent times.

In order to focus on a portfolio that delivers on global strategic priorities, Medtronic decided to divest part of its PMR (patient monitoring and recovery) division within MITG (Minimally Invasive Therapies Group) business to Cardinal Health for a deal value of $6.1 billion.

Following the announcement of its two major buyouts, Abbott divested its eye care business Abbott Medical Optics to Johnson & Johnson for about $4.33 billion to streamline its newly added business lines. The AMO product lines have joined JNJ’s ACUVUE Brand Contact Lenses business, and the combined organization will operate under the brand name Johnson & Johnson Vision.

A marketer of aesthetic treatment systems, Cynosure, recently sold itself to Hologic, Inc. (NASDAQ: HOLX Free Report ). Notably, Hologic acquired all outstanding Cynosure shares for approximately $1.65 billion.

Wright Medical’s (NASDAQ: WMGI Free Report ) recent divestiture of its large joints (hip/knee) business to Corin Orthopaedics is an example of the focus that the former puts on its core businesses.

Emerging Market Openings

According to a report by Visiongain, the global medical devices market will reach $398 billion in 2017 from $321 billion in 2012. This trend will continue to grow stronger through 2023.

The traditional market remains plagued by growing regulatory scrutiny, pricing pressure and no sign of a turnaround in the emerging markets of Latin America and Eastern Europe as per recent data from Euromonitor International. So, it’s the Asia Pacific region on which all the bets are being placed this year.

China and India’s healthcare service revenues are expected to grow at a massive rate, resulting in a large number of new hospital construction projects and soaring demand for medical and surgical equipment.

Abbott continues to lead the emerging market investment trend with about 50% of sales from this region. In recent quarters, sales in key emerging markets climbed in double digits driven by growth in BRIC as well as strong growth in several countries throughout Latin America, including Colombia, Mexico, Peru and Argentina.

At Medtronic, in the fourth quarter of fiscal 2017, business in China, Latin America and Southeast Asia showed sustained strength, growing by strong double digits. Eastern Europe on the other hand grew high single digits.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on TFX - FREE

Get the full Report on MDT - FREE

Get the full Report on JNJ - FREE

Get the full Report on HOLX - FREE

Get the full Report on WMGI - FREE

Follow us on Twitter:

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Re...

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Teleflex Incorporated (TFX): Free Stock Analysis Report
 
Medtronic PLC (MDT): Free Stock Analysis Report
 
Johnson & Johnson (JNJ): Free Stock Analysis Report
 
Hologic, Inc. (HOLX): Free Stock Analysis Report
 
Wright Medical Group N.V. (WMGI): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research